First-of-its-Kind CorVista® System Developed for Suspected Pulmonary Hypertension

CorVista Health developed novel CorVista® System, the first non-invasive point-of-care diagnostic solution to treat patients with suspected pulmonary hypertension.

CorVista System is a non-invasive point-of-care solution which collects patient’s cardiac and hemodynamic signals and applies machine learning to predict the likelihood of cardiovascular diseases without the need of using radiation, contrast agents, injections, fasting or exercise.

The non-invasive diagnostic test is designed for patients with suspected pulmonary hypertension (PH), a type of high blood pressure affecting the arteries in the lungs and the heart. The novel non-invasive CorVista System will help clinicians to diagnose pulmonary hypertensionin patients at an earlier stage.

Compared to the current standard of care for diagnosing pulmonary hypertension, the CorVista System offers two significant improvements such as population expansion for the use of a non-invasive, point-of-care test and reduces the time to diagnosis and treatments by improving the overall patient outcomes.

Pulmonary arterial hypertension is a serious disease causing right ventricular pressure/volume overload, right ventricular failure, andearly death. The disease is challenging to diagnose, affecting 1 percent of the global population and up to 10 percent of people greater than 65 years of age and 50 percent of patients with heart failure.

The System is not yet FDA cleared, but once approved the new CorVista System will help the patients access to as a non-invasive point of care diagnostic solution.